{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:30:20Z","timestamp":1793773820101,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014481","name":"Kite Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jtct.2024.06.016","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T03:33:09Z","timestamp":1718767989000},"page":"885.e1-885.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Matching-Adjusted Indirect Comparisons of Axicabtagene Ciloleucel to Mosunetuzumab for the Treatment of Relapsed\/Refractory Follicular Lymphoma"],"prefix":"10.1016","volume":"30","author":[{"given":"Markqayne D.","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0322-5398","authenticated-orcid":false,"given":"Steve","family":"Kanters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Beygi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Best","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Limbrick-Oldfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-9641","authenticated-orcid":false,"given":"Olalekan O.","family":"Oluwole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jtct.2024.06.016_bib0001","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood-2006-10-041863","article-title":"How I treat indolent lymphoma","volume":"109","author":"Gribben","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2024.06.016_bib0002","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.24086","article-title":"Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011","volume":"90","author":"Al-Hamadani","year":"2015","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.jtct.2024.06.016_bib0003","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/2040620717738740","article-title":"The evolving role of targeted biological agents in the management of indolent B-cell lymphomas","volume":"8","author":"Wang","year":"2017","journal-title":"Ther Adv Hematol"},{"issue":"7","key":"10.1016\/j.jtct.2024.06.016_bib0004","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.jtct.2024.06.016_bib0005","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.06.016_bib0006","unstructured":"Food and Drug Administration. FDA approves axicabtagene ciloleucel for large B-cell lymphoma. 2017; Available at: https:\/\/tinyurl.com\/3bdezy3p. Accessed October 14, 2023."},{"key":"10.1016\/j.jtct.2024.06.016_bib0007","unstructured":"Food and Drug Administration. FDA approved axicabtagene ciloleucel for large B-cell lymphoma. 2021; Available at: https:\/\/tinyurl.com\/yc2cp7mk. Accessed October 14, 2023"},{"key":"10.1016\/j.jtct.2024.06.016_bib0008","unstructured":"Gilead. Kite\u2019s CAR T-cell Therapy Yescarta\u00ae Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma. 2022; Available at: https:\/\/shorturl.at\/wxAIo. Accessed October 14, 2023."},{"issue":"1","key":"10.1016\/j.jtct.2024.06.016_bib0009","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2024.06.016_bib0010","unstructured":"European Medicines Agency 2022; Available at:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kymriah. Accessed October 15, 2023."},{"key":"10.1016\/j.jtct.2024.06.016_bib0011","unstructured":"Food and Drug Administration. FDA approves tisagenlecleucel for relapsed or refractory follicular lymphoma. 2022. Available at: https:\/\/shorturl.at\/sOoUK. Accessed October 15, 2023."},{"key":"10.1016\/j.jtct.2024.06.016_bib0012","unstructured":"Food and Drug Administration. FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma. 2022; Available at:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma. Accessed January 3, 2023."},{"issue":"8","key":"10.1016\/j.jtct.2024.06.016_bib0013","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncoly"},{"issue":"10","key":"10.1016\/j.jtct.2024.06.016_bib0014","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jtct.2024.06.016_bib0015","series-title":"NICE DSU Technical Support Document 18: Methods for Population-Adjusted Indirect Comparisons in Submissions to NICE","author":"Phillippo","year":"2016"},{"key":"10.1016\/j.jtct.2024.06.016_bib0016","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"10.1016\/j.jtct.2024.06.016_bib0017","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0272989X16670604","article-title":"Extrapolation of survival curves from cancer trials using external information","volume":"37","author":"Guyot","year":"2017","journal-title":"Med Decis Making"},{"issue":"1","key":"10.1016\/j.jtct.2024.06.016_bib0018","article-title":"A method for reconstructing individual patient data from Kaplan-Meier survival curves that incorporate marked censoring times","volume":"7","author":"Rogula","year":"2022","journal-title":"MDM Policy Pract"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2024.06.016_bib0019","doi-asserted-by":"crossref","first-page":"10380","DOI":"10.1182\/blood-2022-156120","article-title":"3-Year follow-up analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL)","volume":"140","author":"Neelapu","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2024.06.016_bib0020","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2021014375","article-title":"Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma","volume":"140","author":"Ghione","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2024.06.016_bib0021","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2024.06.016_bib0022","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1182\/blood-2022-157691","article-title":"Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed\/refractory follicular lymphoma who received \u22652 prior therapies: updated results from a pivotal phase II study","volume":"140","author":"Bartlett","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2024.06.016_bib0023","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.clml.2023.09.007","article-title":"Indirect treatment comparisons of mosunetuzumab with third- and later-line treatments for relapsed\/refractory follicular lymphoma","volume":"24","author":"Bosch","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2024.06.016_bib0024","unstructured":"Carter D. Bispecifics Antibodies: The next Big Thing in Lymphoma Treatment. CancerWise, MD Anderson Cancer Center. Houston, TX 2022. Available at: https:\/\/shorturl.at\/3LORb. Accessed November 28, 2023."},{"key":"10.1016\/j.jtct.2024.06.016_bib0025","unstructured":"Business Wire. Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland. 2022. Available at: https:\/\/shorturl.at\/GICQ4. Accessed October 15, 2023."},{"issue":"16_suppl","key":"10.1016\/j.jtct.2024.06.016_bib0026","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1200\/JCO.2023.41.16_suppl.7509","article-title":"Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R\/R) follicular lymphoma (FL)","volume":"41","author":"Jacobson","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.06.016_bib0027","series-title":"Matching-Adjusted Indirect Comparison of Efficacy and Safety for Tisagenlecleucel and Mosunetuzumab in Patients (PTS) with Relapsed\/Refractory Follicular Lymphoma (r\/r FL)","author":"Fowler","year":"2023"},{"issue":"2","key":"10.1016\/j.jtct.2024.06.016_bib0028","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med Decis Making"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724004731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724004731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T07:21:35Z","timestamp":1724397695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724004731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2666636724004731"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.06.016","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Matching-Adjusted Indirect Comparisons of Axicabtagene Ciloleucel to Mosunetuzumab for the Treatment of Relapsed\/Refractory Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}